SecBot SecBot
SECBOTREPLAY Home › Report › MYGN

MYGN · Myriad Genetics announced it will present data at ASCO 2026 showing its…

Myriad Genetics, Inc. · PRESS-RELEASE filed May 27, 2026 at 09:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 27, 2026 at 09:05 ET

Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection across multiple cancer types in the MONSTAR-SCREEN-3 study, with 16% of samples detected at ultrasensitive levels. The data supports the clinical utility of the test for recurrence monitoring, but this is a scientific conference presentation with no immediate revenue or regulatory catalyst.

  • Precise MRD test achieved 97% baseline ctDNA detection in MONSTAR-SCREEN-3 pan-cancer analysis
  • 16% of samples detected in the ultrasensitive range
  • ctDNA-positive patients at 1-month post-surgery had significantly worse disease-free survival
  • Data presented across six posters at ASCO 2026 covering gastric, ovarian, head/neck, sarcoma, and pan-cancer indications

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access